Drugs / ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05153226 Comparator | Mar 2022 → Jun 2025 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, graft versus host disease, myelodysplastic syndrome | DKMS | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05153226 ↗ |
| Route | Intravenous | “10 mg/kg i.v. d-3, d-2, d-1 pre-transplant” NCT05153226 ↗ |